RT Journal Article
SR Electronic
T1 Human serum from SARS-CoV-2 vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.10.21267523
DO 10.1101/2021.12.10.21267523
A1 Schubert, Maren
A1 Bertoglio, Federico
A1 Steinke, Stephan
A1 Heine, Philip Alexander
A1 Ynga-Durand, Mario Alberto
A1 Zuo, Fanglei
A1 Du, Likun
A1 Korn, Janin
A1 Milošević, Marko
A1 Wenzel, Esther Veronika
A1 Maass, Henrike
A1 Krstanović, Fran
A1 Polten, Saskia
A1 Pribanić-Matešić, Marina
A1 Brizić, Ilija
A1 Piralla, Antonio
A1 Baldanti, Fausto
A1 Hammarström, Lennart
A1 Dübel, Stefan
A1 Šustić, Alan
A1 Marcotte, Harold
A1 Strengert, Monika
A1 Protić, Alen
A1 Pan-Hammarström, Qiang
A1 Čičin-Šain, Luka
A1 Hust, Michael
YR 2021
UL http://medrxiv.org/content/early/2021/12/15/2021.12.10.21267523.abstract
AB The COVID-19 pandemic is caused by the betacoronavirus SARS-CoV-2. In November 2021, the Omicron variant was discovered and classified as a variant of concern (VOC). Omicron shows substantially more mutations in the spike protein than any previous variant, mostly in the receptor binding domain (RBD). We analyzed the binding of the Omicron RBD to the human ACE2 receptor and the ability of human sera from COVID-19 patients or vaccinees in comparison to Wuhan, Beta or Delta RBDs variants.All RBDs were produced in insect cells. RBD binding to hACE was analyzed by ELISA and microscale thermophoresis (MST). Similarly, sera from 27 COVID-19 patients, 21 fully vaccinated individuals and 16 booster recipients were titrated by ELISA on the fixed RBDs from the original Wuhan strain, Beta, Delta and Omicron VOC.Surprisingly, the Omicron RBD showed the weakest binding to ACE2, arguing that improved ACE2 binding is not a likely driver of Omicron evolution. Serum antibody titers were significantly lower against Omicron RBD than against the original Wuhan strain. Serum titers against Beta and Delta RBDs were also reduced, but to a lesser degree. The reduced binding of sera to Omicron RBD adds evidence that current vaccination protocols may be less efficient against the Omicron variant.Competing Interest StatementM.S., F.B., S.S., S.D. and M.H. are inventors on a patent application on blocking antibodies against SARS-CoV-2. S.D. and M.H. are co-founders and shareholder of CORAT Therapeutics GmbH, a company founded for clinical and regulatory development of COR-101, an antibody for the treatment of hospitalized COVID-19 patients. S.D. and E.V.W. are co-founders and shareholders of Abcalis GmbH, a company producing antibodies for diagnostics of SARS-CoV-2.Funding StatementWe kindly acknowledge the financial support of the European Union for the ATAC ("antibody therapy against corona", Horizon2020 number 101003650), the MWK Niedersachsen(14-76103-184 CORONA-2/20) for the projects "Antibody generation", "Neutralization experiments" and "Structure-based analysis of antiviral strategies against CoV-2 target proteins" and the Deutsche Herzstiftung ("Menschliche monoklonale Antikoerper gegen SARS-CoV2 zur Prophylaxe gegen COVID-19 bei vorerkrankten Risikopatienten - Unterstuetzung der Entwicklung") and the Swedisch Research Council. LCS was supported by grants from the Helmholtz Association (EU-Partering PIE-0008 and Helmholtz campaign COVIPA).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval was given from the ethical committee of the Technische Universitaet Braunschweig (Ethik-Kommission der Fakultaet 2 der TU Braunschweig, approval number FV-2020-02) and the approval of the Ethical Commission of Hannover Medical School (Nr. 9254_BO_K_2020). The study in Italy was performed under the approval of the Institutional Review Board of Policlinico San Matteo (protocol number P_20200029440). The study in Sweden was approved by the ethics committee in Stockholm (Dnr 2020-02646).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors